Last reviewed · How we verify
3ml-Rejuvinex
3ml-Rejuvinex is a regenerative medicine product designed to promote tissue repair and rejuvenation through cellular and growth factor delivery.
3ml-Rejuvinex is an autologous adipose-derived stem cell therapy that promotes tissue regeneration and rejuvenation through paracrine signaling and differentiation. Used for Tissue regeneration and rejuvenation (aesthetic and reconstructive applications).
At a glance
| Generic name | 3ml-Rejuvinex |
|---|---|
| Also known as | PDRN (Polydeoxyribonucleotide) sodium |
| Sponsor | Seoul National University Bundang Hospital |
| Drug class | Autologous cell therapy |
| Modality | Small molecule |
| Therapeutic area | Regenerative Medicine |
| Phase | FDA-approved |
Mechanism of action
The product appears to be a cell-based or biologics therapeutic intended for aesthetic and regenerative applications. It likely works by delivering bioactive components that stimulate tissue remodeling, collagen production, and cellular renewal in treated areas. The exact molecular mechanisms are not publicly detailed in standard pharmaceutical databases.
Approved indications
- Tissue rejuvenation and regeneration (aesthetic indication)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 3ml-Rejuvinex CI brief — competitive landscape report
- 3ml-Rejuvinex updates RSS · CI watch RSS
- Seoul National University Bundang Hospital portfolio CI